Peptide Sciences closed on March 6, 2026 without a stated reason, posting only a brief farewell notice and no process for pending orders. The closure came in the middle of the largest regulatory enforcement wave the research peptide market has seen, and the timing rather than any announcement is the basis for the widely held view that the company closed pre-emptively. This September update builds on the original Peptide Sciences shutdown coverage from March and the broader 2026 vendor shutdown roundup from June. Nothing has changed in the company's status since: the domain does not resolve to a storefront, no successor entity has announced itself, and no public statement from the principals has appeared as of the first week of September.
The enforcement context that surrounded the closure is documented. Beginning in September 2025 the FDA issued more than fifty warning letters to peptide vendors and related businesses, targeting products labeled for research but marketed for human use. In the same period, Eli Lilly and Novo Nordisk pursued litigation against GLP-1 compounders and sellers, and federal prosecutors secured guilty pleas from individuals tied to grey-market peptide distribution. A vendor operating at Peptide Sciences' scale, estimated by traffic analysts at several million dollars per month, faced a materially different risk profile by early 2026 than it had a year earlier. Whether that calculation drove the decision is inference. The observable facts are the date, the absence of a stated reason, and the enforcement environment.
What is the status of Amino Asylum?
Amino Asylum has been offline since approximately June 18, 2025, when federal authorities executed a search at its warehouse. The website went dark immediately, payment processing was terminated, and open orders were frozen. As of September 2026 the site has not returned, and no announcement of reopening or successor operation has been made. Amino Asylum sold amino acids, peptides, methylene blue, and other compounds, and its closure is generally counted as the start of the 2025 to 2026 shutdown wave.
Searches for "Amino Asylum shut down" continue to land on Amino Foundry because of the shared "amino" prefix. The two companies are unrelated. Amino Foundry has no connection to Amino Asylum's operations, principals, inventory, or customer records.
Did Science.bio close?
Science.bio closed permanently on January 27, 2026. Unlike Amino Asylum, the closure was announced by the company itself rather than forced by a raid, and no criminal charges have been reported against its founders. Published accounts of the closure cite the same pressures that shaped the rest of the wave: the FDA warning letter campaign, a large U.S. Customs and Border Protection interdiction of mis-manifested peptide shipments from China, and manufacturer litigation over GLP-1 products. Science.bio was primarily known for small-molecule research compounds rather than peptides, but its exit removed one of the longer-standing names in the research chemical market.
What about Paradigm Peptides and Pure Peptide Labs?
Paradigm Peptides' status was covered in the June roundup and has not changed. Pure Peptide Labs is a name that appears in search traffic to this site, but as of publication its status is unconfirmed: public reporting does not establish a closure date or an operating storefront with certainty, and this article does not assert either. Researchers checking on any specific vendor should apply the verification steps in the June roundup: confirm the domain resolves to a live storefront with recent inventory updates, confirm a working payment path, confirm a reachable support contact, and check for recent third-party testing on current lots.
What happened with the FDA advisory committee vote on BPC-157?
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to consider whether seven peptide bulk drug substances, including BPC-157, should be eligible for pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The committee voted 8 to 6 with one abstention to recommend adding BPC-157 to the 503A bulks list, over the objection of FDA scientific staff who described the compound as not well characterized and the evidence for its proposed indication as lacking. The original advisory committee coverage has the full breakdown of the meeting.
The committee's recommendation is non-binding. As of September 2026 the FDA has not announced whether it will accept it, and no peptide from the July meeting has been added to the 503A bulks list. If the agency accepts the recommendation, it must proceed through notice-and-comment rulemaking before the listing takes effect, a process that typically runs months at minimum. If it rejects the recommendation, the compound remains outside the compounding pathway. The distinction matters for the research market in one specific way: a 503A listing would create a legal route for licensed compounding pharmacies to prepare BPC-157 on prescription, which is a separate channel from research-use supply and does not change the regulatory status of research-grade material.
Commentary in health policy outlets has framed the vote as a potential back door for unapproved peptides into clinical use. That framing is a policy argument, not a regulatory outcome, and the outcome is still pending.
How many research peptide vendors have closed since mid-2025?
Published trackers count at least eight grey-market research peptide vendors closing between mid-2025 and early 2026, with Amino Asylum, Science.bio, and Peptide Sciences the three largest. The count varies by source depending on how a closure is defined; several smaller vendors went offline without announcement and may or may not return. The June roundup lists the confirmed cases with dates.
The pattern across the confirmed closures is consistent. Vendors that marketed research compounds with language implying human use, that sold GLP-1 class compounds at volume, or that operated without documented third-party testing were the ones that received warning letters, litigation, or enforcement visits. Vendors that maintained strict research-use labeling and published batch-level testing have, so far, been outside the enforcement actions that are public.
What should researchers watch in the fourth quarter of 2026?
Three items. First, the FDA's decision on the July advisory committee recommendations, which will set the regulatory direction for BPC-157 and the other six peptides considered. Second, any further FDA warning letter batches; the agency's September 2025 campaign was the trigger for the shutdown wave, and a repeat would likely produce another round of closures. Third, the retatrutide phase 3 program, which reported TRIUMPH-1 in May and TRIUMPH-2 and TRIUMPH-3 in July, with a regulatory submission planned for the first quarter of 2027. That program's progress drives demand and pricing for the research-market triple agonist sold under the GLP-3 label, and it is the compound class most exposed to manufacturer litigation.
Amino Foundry will update this series as vendor status changes are confirmed. Claims about any vendor's status in this article are limited to what is publicly observable: whether a site is online, what the company itself has announced, and what regulators have published.
All compounds referenced in this article are supplied for research purposes only and are not for human use. Nothing here describes or endorses any use of these materials outside laboratory research. These products are not intended to diagnose, treat, cure, or prevent any disease.
Stay in the loop
New compounds, research updates & exclusive subscriber deals.
